Skip to main content

Advertisement

Springer Nature Link
Log in

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objective

To evaluate neoadjuvant sunitinib in patients with synchronous metastatic renal cell cancer (mRCC) to downsize surgically complex tumours and reconsider cytoreductive surgery.

Patients and methods

Retrospective analysis of ten consecutive mRCC patients treated with sunitinib in an expanded access program who presented with surgically complex primary tumours or bulky locoregional metastases. Surgery-limiting tumour sites (SLTSs) were defined as primary or retroperitoneal lesions with direct invasion of adjacent organs or encasement of vital structures on imaging. Patients received sunitinib 50 mg/day for 4 weeks on and 2 weeks off to be followed by cytoreductive surgery after downsizing and individual reassessment. Response was measured according to Response Evaluation Criteria in Solid Tumours (RECIST).

Results

Six out of ten SLTSs revealed a reduction of tumour size with a median of 14% according to RECIST. None of the ten SLTSs had a partial response (PR), whilst at distant metastatic sites one complete remission and two PRs occurred. Downsizing of SLTSs appeared most prominent in the first 2–4 months, which resulted in reconsidering cytoreductive nephrectomy in three patients. These three tumours invaded the liver on imaging and were reduced by 11, 18 and 20%.

Conclusions

In this patient group with mRCC and surgically complex primary tumours or locoregional metastases, downsizing of SLTSs by neoadjuvant sunitinib was limited. Cytoreductive surgery was reconsidered in three patients. Given the overall reduction in tumour burden by sunitinib alone, further investigation to define the role of cytoreductive surgery is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608. doi:10.1200/JCO.2006.08.5415

    Article  PubMed  CAS  Google Scholar 

  2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124. doi:10.1056/NEJMoa065044

    Article  PubMed  CAS  Google Scholar 

  3. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast GC, Haanen J, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14:2431–2436. doi:10.1158/1078-0432.CCR-07-4089

    Article  PubMed  Google Scholar 

  4. Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, de Gast GC (2006) Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 49:76–81. doi:10.1016/j.eururo.2005.09.011

    Article  PubMed  Google Scholar 

  5. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102:692–696

    Article  PubMed  Google Scholar 

  6. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296. doi:10.1200/JCO.20.1.289

    Article  PubMed  CAS  Google Scholar 

  7. Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, Wilding G, Motzer RJ (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25:5027 (Meeting abstracts)

    Google Scholar 

  8. Chow LQM, Eckhardt SG (2007) Sunitinib: from rationale design to clinical efficacy. J Clin Oncol 25:884–896. doi:10.1200/JCO.2006.06.3602

    Article  PubMed  CAS  Google Scholar 

  9. Mancuso M, Davis R, Norberg S, O’Brien S, Sennino B, Nakahara T, Yao V, Inai T, Brooks P, Freimark B, Shalinsky D, Hu-Lowe D, McDonald D (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621. doi:10.1172/JCI24612

    Article  PubMed  CAS  Google Scholar 

  10. Jain R, Tong R, Munn L (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:2729–2735. doi:10.1158/0008-5472.CAN-06-4102

    Article  PubMed  CAS  Google Scholar 

  11. Beisland C, Medby PC, Sander S, Beisland HO (2000) Nephrectomy— indications, complications and postoperative mortality in 646 consecutive patients. Eur Urol 37:58–64. doi:10.1159/000020101

    Article  PubMed  CAS  Google Scholar 

  12. Wood CG (2007) Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 13:697s–702s. doi:10.1158/1078-0432.CCR-06-2109

    Article  PubMed  Google Scholar 

  13. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Spiess PE, Wood CG (2007) Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology 69:835–838. doi:10.1016/j.urology.2007.01.034

    Article  PubMed  Google Scholar 

  14. Moul JW, Foley JP, Wind GG, Rubin S, Coffey JA, McLeod DG (1991) Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma. J Urol 164:1104–1107

    Google Scholar 

  15. Kelly R, Skinner D, Yellin AE, Weaver FA (1995) En bloc aortic resection for bulky metastatic germ cell tumors. J Urol 153:1849–1851. doi:10.1016/S0022-5347(01)67328-2

    Article  PubMed  CAS  Google Scholar 

  16. Spitz A, Wilson TG, Kawachi MH, Ahlering TE, Skinner DG (1997) Vena caval resection for bulky metastatic germ cell tumors: an 18 year experience. J Urol 158:1813–1818. doi:10.1016/S0022-5347(01)64137-5

    Article  PubMed  CAS  Google Scholar 

  17. Sawczuk IS, Pollard JC (1999) Renal cell carcinoma: should radical nephrectomy be performed in the presence of metastatic disease? Curr Opin Urol 9:377–381. doi:10.1097/00042307-199909000-00002

    Article  PubMed  CAS  Google Scholar 

  18. Sengupta S, Leibovich BC, Blute ML, Zincke H (2005) Surgery for metastatic renal cell cancer. World J Urol 23:155–160. doi:10.1007/s00345-005-0504-6

    Article  PubMed  Google Scholar 

  19. Yonover PM, Flanigan RC (2000) Should radical nephrectomy be performed in the face of surgically incurable disease? Curr Opin Urol 10:429–434. doi:10.1097/00042307-200009000-00011

    Article  PubMed  CAS  Google Scholar 

  20. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int 100:755–759. doi:10.1111/j.1464-410X.2007.07108.x

    Article  PubMed  Google Scholar 

  21. Reznek RH (1996) Imaging in the staging of renal cell carcinoma. Eur Radiol 6:120–128

    PubMed  CAS  Google Scholar 

  22. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764. doi:10.1200/JCO.2006.07.3411

    Article  PubMed  Google Scholar 

  23. Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P (2007) Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53:845–848

    Article  PubMed  Google Scholar 

  24. Pantuck AJ, Belldegrun AS, Figlin RA (2007) Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res 13:693s–696s. doi:10.1158/1078-0432.CCR-06-1916

    Article  PubMed  Google Scholar 

  25. Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076. doi:10.1097/01.ju.0000110610.61545.ae

    Article  PubMed  Google Scholar 

  26. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970. doi:10.1016/S0140-6736(01)06103-7

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    Axel Bex & Simon Horenblas

  2. Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    Christian Blank & John Haanen

  3. Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

    Astrid A. M. van der Veldt, Alfons J. M. van den Eertwegh & Epie Boven

Authors
  1. Axel Bex
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Astrid A. M. van der Veldt
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Christian Blank
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Alfons J. M. van den Eertwegh
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Epie Boven
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Simon Horenblas
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. John Haanen
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Axel Bex.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bex, A., van der Veldt, A.A.M., Blank, C. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27, 533–539 (2009). https://doi.org/10.1007/s00345-008-0368-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-008-0368-7

Keywords